Biomarker Testing in Non-Small Cell Lung Carcinoma: Performance and Patient Outcomes

被引：0
|
作者：
Fadel, Saleh [1 ]
Chirip, Venus [2 ]
Wheatley-Price, Paul [3 ]
Reaume, Neil [3 ]
Lo, Bryan [1 ]
Chang, Nina [4 ]
Sekhon, Harmanjatinder [4 ]
Gomes, Marcio [1 ]
机构：
[1] Univ Ottawa, Ottawa Hosp, Ottawa, ON, Canada
[2] Eastern Ontario Reg Lab Assoc, Ottawa Hosp, Ottawa, ON, Canada
[3] Ottawa Hosp, Ottawa, ON, Canada
[4] Univ Ottawa, Ottawa Hosp, Eastern Ontario Reg Lab Assoc, Ottawa, ON, Canada
来源：
LABORATORY INVESTIGATION | 2021年 / 101卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
923
引用
收藏
页码：1103 / 1104
页数：2
相关论文
共 50 条
  • [21] Biomarker Testing for Guiding Precision Medicine for Patients With Non-Small Cell Lung Cancer
    Fox, Adam H.
    Alexander, Mariam
    Forcucci, Jessica A.
    Silvestri, Gerard A.
    CHEST, 2024, 166 (05) : 1239 - 1249
  • [22] Reirradiation for Locoregionally Recurrent Lung Cancer: Outcomes in Non-Small Cell Lung Carcinoma
    Thakur, N.
    Yadav, R.
    Roy, P.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S939 - S939
  • [23] Outsourcing predictive biomarker testing in non-small cell carcinoma: a personal view of pathologists
    Brcic, Luka
    Kern, Izidor
    TRANSLATIONAL LUNG CANCER RESEARCH, 2020, 9 (05) : 2194 - 2198
  • [24] The association between Medicaid insurance, biomarker testing, and outcomes in patients with advanced non-small cell lung cancer (aNSCLC).
    Gross, Cary Philip
    Meyer, Craig S.
    Ogale, Sarika
    Kent, Matthew
    Wong, William Bruce
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (29)
  • [25] LETM1 is a potential biomarker of prognosis in lung non-small cell carcinoma
    Piao, Longzhen
    Yang, Zhaoting
    Feng, Ying
    Zhang, Chengye
    Cui, Chunai
    Xuan, Yanhua
    BMC CANCER, 2019, 19 (01)
  • [26] LETM1 is a potential biomarker of prognosis in lung non-small cell carcinoma
    Longzhen Piao
    Zhaoting Yang
    Ying Feng
    Chengye Zhang
    Chunai Cui
    Yanhua Xuan
    BMC Cancer, 19
  • [27] Outcomes of Pulmonary Resection in Elderly Non-Small Cell Lung Cancer Patient
    Tantraworasin, A.
    Siwachat, S.
    Tanatip, N.
    Lertprasertsuke, N.
    Kongkarnka, S.
    Euathrongchit, J.
    Wannasopha, Y.
    Suksombooncharoen, T.
    Chewaskulyong, B.
    Taioli, E.
    Saeteng, S.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S651 - S651
  • [28] Predictive Biomarker Testing for Programmed Cell Death 1 Inhibition in Non-Small Cell Lung Cancer
    Sheffield, Brandon S.
    Geller, Georgia
    Pleasance, Erin
    Zachara-Szczakowski, Susanna
    Milne, Katy
    Kalloger, Steve E.
    Zhao, Eric
    Bidnur, Samir
    Jones, Martin
    Nelson, Brad H.
    Yip, Stephen
    Marra, Marco A.
    Laskin, Janessa
    Ho, Cheryl
    Ionescu, Diana
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S199 - S199
  • [29] Radical treatment of synchronous oligometastatic non-small cell lung carcinoma (NSCLC): Patient outcomes and prognostic factors
    Griffioen, Gwendolyn H. M. J.
    Toguri, Daniel
    Dahele, Max
    Warner, Andrew
    de Haan, Patricia F.
    Rodrigues, George B.
    Slotman, Ben J.
    Yaremko, Brian P.
    Senan, Suresh
    Palma, David A.
    LUNG CANCER, 2013, 82 (01) : 95 - 102
  • [30] RADICAL TREATMENT OF SYNCHRONOUS OLIGOMETASTATIC NON-SMALL CELL LUNG CARCINOMA (NSCLC): PATIENT OUTCOMES AND PROGNOSTIC FACTORS
    Griffioen, Gwendolyn H.
    Toguri, Dan
    Dahele, Max
    Warner, Andrew
    De Haan, Patricia F.
    Rodrigues, George
    Slotman, Ben J.
    Senan, Suresh
    Yaremko, Brian P.
    Palma, David
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1220 - S1221
12345